Viral pathogenicity refers to the ability of viruses to cause disease in their host organisms. The degree of pathogenicity varies widely among different viruses and is influenced by factors such as the virus's ability to enter host cells, replicate, evade immune responses, and damage host tissues. Viruses employ diverse mechanisms to exert their pathogenic effects, including the production of toxins, interference with host cell functions, and induction of inflammatory responses. Some viruses are highly pathogenic, causing severe diseases with significant morbidity and mortality, while others may cause mild or asymptomatic infections. Host factors, such as the individual's immune status, genetic makeup, and overall health, also play a crucial role in determining the outcome of a viral infection. Additionally, certain viruses may exhibit tissue tropism, preferring specific cell types or organs for replication. Understanding viral pathogenicity is essential for developing strategies to prevent, treat, and mitigate the impact of viral diseases. Research in this field focuses on unraveling the molecular and cellular mechanisms underlying viral pathogenesis, leading to the development of antiviral drugs, vaccines, and other interventions to combat infectious diseases.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, ItalySubmit your abstract Today
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe